Impact BioMedical Inc. (IBO)
NYSEAMERICAN: IBO · Real-Time Price · USD
0.4547
+0.0030 (0.66%)
Jul 9, 2026, 2:16 PM EDT - Market open
Impact BioMedical Revenue
Impact BioMedical had revenue of $7.00K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $39.00K. In the year 2025, Impact BioMedical had annual revenue of $32.00K.
Revenue (ttm)
$39.00K
Revenue Growth
n/a
P/S Ratio
1,248.79
Revenue / Employee
$19,500
Employees
2
Market Cap
49.03M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 50.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 10.86M |
| CervoMed | 2.09M |
| Hyperion DeFi | 1.04M |
| ABVC BioPharma | 797.92K |
| Mereo BioPharma Group | 500.00K |
IBO News
- 2 months ago - Impact BioMedical Quarterly report: Q1 2026 - Filings
- 3 months ago - Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans - GlobeNewsWire
- 4 months ago - Impact BioMedical Annual report: Q4 2025 - Filings
- 4 months ago - Why Is Impact BioMedical Stock (IBO) Up Today? - TipRanks
- 8 months ago - Impact BioMedical Quarterly report: Q3 2025 - Filings
- 10 months ago - Impact BioMedical Proxy statement: Proxy Filing - Filings
- 11 months ago - Impact BioMedical announces 3F U.S. patent issue - TheFly
- 11 months ago - Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue - GlobeNewsWire